Can a daily pill tame a hidden heart risk?
NCT ID NCT07745114
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called SAL0137 in healthy adults, some with elevated Lp(a), a genetic risk factor for heart disease. The study aims to check the drug's safety, how the body processes it, and its effect on Lp(a) levels. Participants receive either the drug or a placebo, with some taking a single dose and others taking it daily for two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAL0137 tablets
- What this could lead to
- If successful, this could lead to a daily pill that lowers Lp(a), a risk factor for heart disease, potentially reducing cardiovascular risk.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, not effectiveness. The drug may not lower Lp(a) as hoped or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED LP(A) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of ANHUI Medical University
Hefei, Anhui, 230088, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates